Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT

Beam Therapeutics Inc. will present initial data from its Phase 1/2 clinical trial of BEAM-301 for glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the ESGCT from October 27-30, 2026. The data indicate clinical proof of concept for the genetic correction of the R83C mutation, showing restoration of endogenous glucose production and dose-dependent improvements in key endpoints. The safety profile of BEAM-301 aligns with that of other lipid-nanoparticle based therapies.